drugset / Trial / NCT03909152
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
Phase 2
Completed
34 enrolled
Memorial Sloan Kettering Cancer Center
Context Therapeutics Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test any good and bad effect of the study drug, onapristone extended-release (ER) alone and in combination with anastrozole.
Timeline
- Start
- 2019-05-02
- Primary completion
- 2024-09-03
- Completion
- 2024-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | 1 mg | Oral |
| Subject | Onapristone | Other / unclassified | 50 mg | Oral |